Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 26;4(2):00028-2018.
doi: 10.1183/23120541.00028-2018. eCollection 2018 Apr.

Summary of the International Clinical Guidelines for the Management of Hospital-Acquired and Ventilator-Acquired Pneumonia

Affiliations
Free PMC article

Summary of the International Clinical Guidelines for the Management of Hospital-Acquired and Ventilator-Acquired Pneumonia

Antoni Torres et al. ERJ Open Res. .
Free PMC article

Abstract

A summary of the evidence and recommendations made in the ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia http://ow.ly/S3zA30iZfLa.

Conflict of interest statement

Conflict of interest: A. Torres reports grants from MedImmune, Cubist, Bayer, Theravance, and from Poliphor; personal fees from Bayer (Advisory Board), Roche (Advisory Board), The Medicines CO (Advisory Board), and from Curetis (rapid molecular tests) (Advisory Board); grants as the Principal Investigator of a Phase III study of Cefatzidime/Avibactam for HAP/VAP, during the conduct of the study. He has received personal fees from GSK (Educational symposium: Siglo XXI), Pfizer (speaker at sponsored vaccine symposia), Astra Zeneca (speaker at symposia on ceftaroline), and from Biotest Advisory Board (Enriched IgM for severe CAP), outside the submitted work. Conflict of interest: M.S. Niederman reports grants and personal fees from Bayer (inhaled amikacin research grant and consulting) and Merck (nosocomial pneumonia consulting and grant), personal fees from Thermo-Fisher (procalcitonin lectures), Theravance (consulting on telavancin), and Pfizer (consulting on linezolid), during the conduct of the study. Conflict of interest: J. Chastre reports personal fees from Medimmune/AstraZeneca (honoraria for consulting), Bayer (honoraria for consulting), Pfizer (honoraria for lecture), Cubist/Merck (honoraria for data safety committee participation), Aridis (honoraria for consulting and data safety participation), and Astellas (honoraria for consulting), outside the submitted work. Conflict of interest: G. Li Bassi reports grants from Medimmune, Cubist, Covidien, Theravance, Cardeas Pharma, Ciel Medical, Biovo Technologies, and Toray, during the conduct of the study. Conflict of interest: C. Luna reports grants and personal fees from Pfizer, and personal fees from Merck Sharp and Dohne, outside the submitted work. Conflict of interest: D. Rigau is a European Respiratory Society methodologist. Conflict of interest: T. Welte reports personal fees (for lectures/advisory board) from AstraZeneca, Basilea, Bayer, Grifols, Infectopharm, Novartis and Pfizer, research grants from Bayer, Grifols, Novartis and Pfizer, research grants from the EU, German Research Council and German Ministry of Research and Education, during the conduct of the study. He has received personal fees (for lectures/advisory board) from Boehringer, Berlin Chemie, Mundipharma and Insmed, outside the submitted work. Conflict of interest: R. Wunderink reports personal fees from Arsanis, Accelerate Diagnostics, Bayer, Cepheid, GenMark, The Medicines Company, Merck, Nabriva, Polyphor and Shionogi, during the conduct of the study. Conflict of interest: M. Kollef reports personal fees from Accelerate (consultant), Merck (consultant, speaker's bureau), Paratek (consultant) and Allergan (speaker's bureau), outside the submitted work. Conflict of interest: J.F. Timsit reports research grants from Merck and 3M, a research grant to his hospital from Astelas, and educational grants from Gilead; and personal fees (for advisory boards) from Pfizer, Paratek, Merck, Bayer, 3M and Abbott, all outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). MDR: multidrug-resistant; ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus. #: low risk for mortality is defined as a ≤15% chance of dying, a mortality rate that has been associated with better outcomes using monotherapy than combination therapy when treating serious infection [18]. Reproduced from [2].

Comment in

  • Treating nosocomial pneumonia: what's new.
    Frantzeskaki F, Orfanos SE. Frantzeskaki F, et al. ERJ Open Res. 2018 Jun 26;4(2):00058-2018. doi: 10.1183/23120541.00058-2018. eCollection 2018 Apr. ERJ Open Res. 2018. PMID: 29978856 Free PMC article.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Salluh JIF, Souza-Dantas VC, Póvoa P. The current status of biomarkers for the diagnosis of nosocomial pneumonias. Curr Opin Crit Care 2017; 23: 391–397. - PubMed
    1. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50: 1700582. - PubMed
    1. Blanquer J, Aspa J, Anzueto A, et al. Normativa SEPAR: neumonía nosocomial [SEPAR guidelines for nosocomial pneumonia]. Arch Bronconeumol 2011; 47: 510–520. - PubMed
    1. Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014; 10: CD006482. - PubMed
    1. Díaz E, Martín-Loeches I, Vallés J. Neumonía nosocomial [Nosocomial pneumonia]. Enferm Infecc Microbiol Clin 2013; 31: 692–698. - PubMed

LinkOut - more resources

Feedback